Portola Pharma (PTLA) Tops Q4 EPS by 8c

Portola Pharma (NASDAQ: PTLA) reported Q4 EPS of ($0.82), $0.08 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $2.73 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Abercrombie & Fitch (ANF) PT Raised to $153 at UBS on Decent Q2, Stable Trend Across Brands
• Bernstein SocGen on Intuitive Surgical (ISRG): 'We see $400 as a great entry point'